At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 204 enrolled
Drug / intervention
Avelumabdrug
Likely dose
Avelumab 10 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma
EMD Serono Research & Development Institute, Inc.·interventional·Posted Jun 4, 2014·Updated Mar 13, 2024
In Brief
A Phase 2 clinical trial evaluating Avelumab for Carcinoma, Merkel Cell. Completed, enrolled 204 participants across 61 sites in 7 countries.
Detailed Summary
This is a multicenter, international, single-arm, open-label, Phase 2 trial to evaluate the efficacy and safety of avelumab in participants with metastatic Merkel cell carcinoma (MCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Merkel Cell
CountriesAustralia, France, Germany, Italy, Japan, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJun 2014
Enrollment StartJul 2014
Primary CompletionMay 2019
Study CompletionMay 2023
TodayJul 2026
First PostedJun 4, 2014
Enrollment StartJul 3, 2014
Primary CompletionMay 2, 2019
Study CompletionMay 3, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 12.1 years ago
Interventions
Avelumabdrug
Avelumab was administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.